Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease
CAMBRIDGE, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized electromagnetic therapeutics to treat neurodegenerative diseases, today announced the publication of a Phase II trial conducted independently under the leadership of its co-founders, which yielded positive results demonstrating that precision-delivered noninvasive brain stimulation has the potential to slow the progression of cognitive and functional decline in patients with mild-to-moderate dementia due to Alzheimer’s disease. The findings have been published in the peer-reviewed neurology journal Brain.
- Fifty patients were enrolled in the Phase II randomized, double-blind, sham-controlled trial.
- Treatment was well tolerated, and no serious adverse events were observed in patients treated with rTMS for 6 months.
- These unprecedented peer-reviewed clinical results demonstrate the potential for this new class of personalized electromagnetic therapeutics to treat cognitive and functional decline safely and noninvasively in Alzheimers disease patients.
- Sinaptica Therapeutics is a clinical-stage electromagnetic therapeutics company pioneering a personalized noninvasive brain stimulation approach with the potential to revolutionize the treatment of Alzheimers disease (AD).